Unibest

Pharmaceutical intermediates

atrasentan Intermediates

2 pharmaceutical intermediates for atrasentan. Indication: Proteinuria; Immunoglobulin A Nephropathy (IgA Nephropathy).

Submit a ProjectAll intermediates

About atrasentan

Originator
Abbvie
Indication
Proteinuria; Immunoglobulin A Nephropathy (IgA Nephropathy)
Approved Date
04/02/2025
NCE Patent
04/02/2030
DS/DP
08/22/2028

Available intermediates

2 intermediates currently listed for atrasentan. Request specifications, documentation or a quotation for any item below.

atrasentan intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
ethyl trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)pyrrolidine-3-carboxylate178739-07-6//
ethyl (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)pyrrolidine-3-carboxylate (S)-(+) mandelate195529-63-6//

Other programs under A

AbemaciclibAbrocitinibAcalabrutinibAdagrasibAfatinibAfoxolanerAlectinib HydrochlorideAlfacalcidol

Building toward atrasentan?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →